Table 2.
Type of evidence and number of occurrence per selected drug repurposing candidate
| Drug | In vitro results | In vivo results | Human results | Registered trials in databases |
| Arsenic trioxide | 23 | 7 | 0 | 2 |
| Artesunate | 5 | 4 | 0 | 0 |
| Atovaquone | 1 | 1 | 0 | 0 |
| Bortezomib | 11 | 4 | 0 | 2 |
| Cetuximab | 7 | 2 | 8 | 8 |
| Chlorpromazine | 3 | 0 | 1 | 0 |
| Cidofovir | 6 | 6 | 3 | 2 |
| Decitabine | 21 | 0 | 2 | 0 |
| Deferoxamine | 2 | 2 | 0 | 0 |
| Doxycycline | 4 | 3 | 0 | 1 |
| Erlotinib | 4 | 1 | 4 | 2 |
| Everolimus | 3 | 0 | 1 | 2 |
| Fulvestrant | 3 | 1 | 0 | 1 |
| Gefitinib | 4 | 0 | 4 | 2 |
| Hydralazine | 7 | 1 | 3 | 3 |
| Interferon α-2b | 9 | 2 | 18 | 1 |
| Ipilimumab | 0 | 0 | 2 | 6 |
| Lovastatin | 3 | 0 | 1 | 0 |
| Lurbinectedin | 2 | 2 | 0 | 0 |
| Melatonin | 5 | 2 | 0 | 0 |
| Metformin | 20 | 6 | 4 | 3 |
| Mifepristone | 9 | 2 | 0 | 0 |
| Nelfinavir | 6 | 3 | 0 | 3 |
| Niclosamide | 1 | 0 | 0 | 0 |
| Nicotinamide | 1 | 1 | 1 | 0 |
| Niraparib | 0 | 0 | 0 | 4 |
| Olaparib | 4 | 2 | 0 | 6 |
| Pazopanib | 0 | 0 | 1 | 3 |
| Plerixafor | 4 | 3 | 0 | 0 |
| Porfimer | 2 | 0 | 1 | 0 |
| Ribavirin | 2 | 2 | 0 | 0 |
| Ribociclib | 2 | 1 | 0 | 0 |
| Rucaparib | 2 | 1 | 0 | 3 |
| Ruxolitinib | 1 | 1 | 0 | 0 |
| Sacituzumab govitecan | 1 | 1 | 0 | 0 |
| Sonidegib | 1 | 1 | 0 | 0 |
| Valproic acid | 11 | 7 | 3 | 4 |
| Zoledronic acid | 4 | 2 | 0 | 1 |